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The clinical studies on this subject in Russia are subject to serious limitations. Spontaneous variability in clinical status and in the severity and frequency of symptoms is notorious in patients with coronary heart disease. The use of these criteria, particularly subjective reports of angina pectoris, is difficult and hazardous under the best of circumstances. The double-blind experiment, with a placebo control, which we now consider to be essential in the evaluation of drug therapy where subjective criteria are involved, does not seem to have been used in any of the Russian studies.
It is not even clear that other treatment, including dietary management, was discontinued or kept absolutely constant during the trials with vitamins but it does appear that the patients knew when they were being given vitamin therapy. Since a large proportion of patients with coronary heart disease report benefit from any treatment, including placebos, it is not surprising than many not occur with the cholesterol feeding alone but the addition of thrombin injections, pituitrin, or extreme exercise produced areas of necrosis in the myocardium of some rabbits. The influence of simultaneous vitamin treatment in these situations has not been reported.
Fedoseev13, 14 reported spontaneous electrocardiographic changes in dogs treated with thiouracil and fed massive doses of cholesterol. Atherosclerosis both in the aorta and in the coronary arteries, but not infarction, was observed in dogs treated in this way. 15 As mentioned above, statistical tests of significance were not made in the Russian studies on atherosclerosis. We have supplied these for all their studies where sufficient data were reported.
Vitamin C
The relationship of this vitamin, as well as vitamin A, to the problem of atherosclerosis probably was studied first by I. A. Miasnikova,18 who used rabbits fed massive doses of cholesterol. Her original publication is not accessible to us but the essential results were reproduced by A. L. Miasnikov in 1954. 19 The conclusion was that vitamin A accentuates and vitamin C inhibits the atherosclerosis produced by cholesterol feeding. In another early paper (1952) it was reported that treatment with ascorbic acid delays the serum cholesterol rise in rabbits fed cholesterol.
These findings were quickly applied to clinical trials. In 1952 Tiapina21 intravenously administered 500 mg. of ascorbic acid daily for several weeks to patients with coronary heart disease and reported a substantial decrease in the serum cholesterol concentration, as much as 150 mg. per 100 ml. in one patient. Later (1954) A. L. Miasnikov22 reported that ascorbic acid lowered the hypercholesteremia of cholesterol-fed rabbits. The data are inadequate to judge whether the difference was statistically significant. Loviagina's and Sinitsina's data23 show a high degree of variability in the serum cholesterol levels of rabbits treated with cholesterol for 105 days.
The treatment of patients with coronary heart disease by intravenous solution of as- Lobova29 found that daily intravenous administration of 1,000 mg. of ascorbic acid for 10 days produced a decrease in the beta and an increase in the alpha lipoproteins in 18 among 35 patients. The responders were stated to be in an early phase of the disease, while the 17 refractory patients were described as being in a more advanced phase.
There are some discrepancies in the reports of clinical benefits. Various studies report subjective improvement in feeling and work capacity with no specific data on controls. Lobova29 reported that ascorbic acid improved the work capacity without change in the severity or frequency of angina. Fedorova (reported by Miasnikov28) found fewer anginal attacks in patients on ascorbic acid therapy.
Ascorbic acid is recommended as an auxiliary in the treatment of patients with coronary artery disease by such leading Russian cardiologists as Miasnikov,22 28, 30, 31 Il'inskii,32 and Ryss.33 The daily dosage advised is 500 to 1,000 mg. orally or 300 to 500 mg. intravenously (in glucose or physiologic saline solution). With the intravenous therapy the recommendation is a series of 20 to 30 daily injections to be repeated at intervals of 2 to 3 months. A favorable feature is stated to be that in the doses used ascorbic acid does not affect blood coagulation. 28 When the cholesterol feeding was discontinued after 105 days, the regressive changes were followed with two groups of nine rabbits each roughly matched in regard to serum cholesterol level. 60 The serum cholesterol concentration in the control group fell from 787 to 285 mg. per 100 ml. in 112 days, while the value in the group receiving vitamin B12 fell from 740 to 142 mg. per 100 ml. Individual data and statistical analysis are not reported but it seems probable that there was a significant difference between the two groups in the regression of hypercholesteremia.
Ignatova59 made planimetric measurements of the areas of the lesions in the aortas stained with Sudan III and examined sections of the walls microscopically from which it was concluded that the severity of the atherosclerosis was considerably greater in the control rabbits than in the rabbits treated with vitamin B12. * On the basis of these results, Miasnikov28 recommends the use of vitamin B12 in a dosage of 0.6 mg. every second day for 2 to 4 weeks for prevention and treatment of atherosclerosis, though he indicates that clinical experience is as yet too limited for conclusive evaluation. Motovilova56 found the prothrombin content of the blood increased in 11 out of 23 patients treated with vitamin B12. Statistical analysis of her results shows an average increase of 10 per cent in the blood prothrombin, and this was statistically highly significant. It may appear, therefore, that treatment with vitamin B12 would be questionable unless combined with anticoagulant treatment.
Choline
In the Russian literature on treatment of patients with atherosclerosis choline is considered together with vitamin therapy.28 32 Pushkar65 reported that the addition of 400 mg. of choline to the daily diet of rabbits fed 200 mg. of cholesterol, did not affect the serum cholesterol level but did delay atherogenesis. Sinitsina66' 67 found a decrease in the serum cholesterol level as well as reduced atherosclerosis in the cholesterol-fed rabbit. In two groups of 21 rabbits each fed cholesterol for 4 months, the mean value was 1,033 mg. per 100 ml. in the control group but only 615 in the group that had received, subcutaneously, 300 to 400 mg. of choline per Kg. of body weight. Our computations indicate that this difference was significant at the level of p = 0.05. Sinitsina67 also reported that the regression of atherosclerosis after discontinuance of cholesterol feeding is accelerated by choline treatment.
Koropova68 found a tendency for the blood cholesterol to fall in 20 patients with coronary heart disease who received, by mouth, 5 Gm. of choline daily for a month. With continued choline dosage in 39 patients for a year, Koropova found that the cholesterol level was decreased in only nine patients, increased in two, and was unchanged in the other 28 patients. Subjective improvement was reported but this may have been the result of suggestion, according to Miasnikov.28 P. M. Savenkov (reported by Lukomskii55) gave 5 to 6 Gm. of choline by mouth daily for 3 weeks to 68 patients with coronary heart disease. Angina pectoris was reported by 35 patients to be significantly reduced, 18 patients said they were slightly improved, 11 patients noted no change, and one patient said he was worse. The serum cholesterol concentration fell, on the average, 40 mg. per 100 ml. in 53 of the 68 patients, a decrease of 15.6 per cent from the initial level. The serum cholesterol level rose in 15 patients, and 11 of these patients had had serum cholesterol values of 200 mg. per 100 ml., or less, before the treatment. Every patient whose initial cholesterol level was over 250 showed a decrease with choline treatment. In 26 of these hypercholesteremic patients measurements were made of the beta lipoproteins in the serum. All showed elevated values before treatment and these fell with treatment in 20 of the 26 patients. Van Chii35 did not find consistent changes of prothrombin and fibrinogen in 38 patients treated with choline (5 Gm. per day) for 10 days.
There is a suggestion in the Russian literature that atherosclerosis is associated with a deficiency of choline or an abnormality in its metabolism. Anisimov69 studied the blood choline content in 21 patients with coronary heart disease and in 33 control subjects. A subnormal level of choline in the blood was found in 11 of the 21 patients and this rose on a daily diet providing 73 Gm. of protein, 53 Gm. of fat, 334 Gm. of carbohydrate, and 1.5 Gm. of choline. It will be noted that this is a low-fat diet (22 per cent of total calories from fats) but we do not know how far it is below the fat content of the usual Russian diet or what other differences were involved.
Lukomskii55 recommends choline administration for the prevention and treatment of atherosclerosis but stresses the necessity for repeated courses of treatment over a long time. The extent to which this treatment is actually used in Russia at present is not clear from the literature.
General Comment
Some of the characteristics of Russian medical research will have been indicated by this review. There is much eagerness to find effective methods of treatment, and a hopeful attitude is evident about medication such as with vitamins. Ascorbic acid is accepted as a standard part of the treatment of patients with coronary heart disease, though it is impossible to judge how many patients actually receive
Circulation. Volume XXIV, November 1961 12.45 this therapy. According to Miasnikov28 it is widespread. It appears likely, too, that treatment with vitamin B12 will receive acceptance. It is curious, however, that massive dosage with nicotinic acid, currently so popular in the United States, has as yet been given little attention in Russia.
The possible mechanisms involved in the reported effects of the vitamins are discussed at length by Russian authors but a presentation of these considerations, some quite speculative, would require far more space than is appropriate to a review devoted to the basic clinical and experimental reports. Obviously, the reports reviewed here require careful consideration. Repetition of some of the studies, with more attention to controls and statistical analysis would be essential for critical evaluation. The great contributions of the pioneering work in Russia on atherosclerosis are obvious to all, and we may be sure that valuable research will continue in that country.
